Cardio

Exponential Health Partners with Cardio Diagnostics to Elevate Cardiovascular Disease Prevention in Michigan

Retrieved on: 
Tuesday, April 9, 2024
Cardiology, Biotechnology, Technology, Health, General Health, Pharmaceutical, Health Technology, Other Technology, Medical Devices, Artificial Intelligence, Genetics, Diagnosis, Exponential, Cardio, Genomics, Cardiovascular disease, Growth, Entrepreneurship, Partnership, Risk, Patient, Artificial intelligence, Splenic infarction, Death, CHD, Medicine, Concierge medicine, Epigenomics, Moyamoya disease, USD, Medical device

As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.

Key Points: 
  • As a result, Exponential Health is expanding access to a new chapter in the proactive management of heart disease.
  • Concierge practices such as Exponential Health are leading the way in adopting epigenetic cardiovascular solutions.
  • "We are thrilled to partner with Dr. Baer and Exponential Health," said Meesha Dogan, Ph.D., CEO and Co-Founder of Cardio Diagnostics.
  • Integrating Cardio Diagnostics' advanced tests into Exponential Health's offerings is a proactive step toward mitigating this global health challenge.

Cardio Diagnostics Holdings, Inc. to Showcase HeartRisk and Actionable Clinical Intelligence Version 3 at the American College of Cardiology’s 73rd Annual Scientific Session

Retrieved on: 
Thursday, March 14, 2024
Other Health, Software, General Health, Data Management, Medical Devices, Technology, Artificial Intelligence, Health Technology, Cardiology, Biotechnology, Other Technology, Health, Cardio, Genomics, Organization, Cardiovascular disease, ACI, Entrepreneurship, Patient, Artificial intelligence, Medicine, CHD, American College, Heart, Epigenomics, Moyamoya disease, ACC, Pharmaceutical industry

Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."

Key Points: 
  • Cardio Diagnostics' mission is in lockstep with this year's ACC.24 conference theme, "Advancing Cardiovascular Care for All."
  • All attendees including providers, provider organizations and potential industry partners will be able to learn more about Cardio Diagnostics' HeartRisk and Actionable Clinical Intelligence platforms at booth 3605.
  • Actionable Clinical Intelligence V.3: Building upon the success of its predecessor, which debuted at ACC in 2023, Actionable Clinical Intelligence V.3 takes precision medicine to new heights.
  • "Our new innovative solutions, HeartRisk and Actionable Clinical Intelligence V.3, can potentially revolutionize how healthcare professionals approach cardiovascular disease prevention, detection and management.

Cardio Diagnostics Holdings, Inc. Expands HeartRisk™ Platform Offering to Diverse Markets in Conjunction with Nationwide Rollout

Retrieved on: 
Thursday, February 15, 2024
General Health, Professional Services, Data Management, Technology, State, Local, Artificial Intelligence, Data Analytics, Cardiology, Biotechnology, Human Resources, Health, Public Policy, Government, Prison, Intelligence, Investment, Smoking, Transport, Conditional sentence, CVD, Cardiovascular disease, Entrepreneurship, Risk, Consultant, Prevalence, Cardio, CHD, Hypertension, Death, Organization, Medicine, Workforce, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, announced today the nationwide rollout and a significant expansion of its groundbreaking HeartRisk™ platform.
  • This expansion extends the reach of its proprietary data intelligence platform to correctional facilities, risk-bearing providers engaged in value-based contracts, and broker and benefits consultants.
  • "By expanding our HeartRisk™ platform, we're not just innovating within traditional healthcare sectors but breaking new ground in diverse markets.
  • From correctional facilities to value-based care providers and workplace wellness programs to brokerage and benefits consultants, our precision cardiovascular solutions provide actionable insights.

Integer to Showcase Recently Acquired Capabilities and New Technologies at MD&M West 2024

Retrieved on: 
Thursday, February 1, 2024
Neuromodulation, Electrophysiology, MD, Integer, Patient, Gen, Second generation, Anaheim Convention Center, Risk, Acquisition, Cardio, Arrhythmia, Blood vessel, Medical imaging

PLANO, Texas, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leader in medical device outsource manufacturing, will join innovators and industry leaders around the world in exhibiting at MD&M West, Feb. 6-8, 2024, at the Anaheim Convention Center in Anaheim, California.

Key Points: 
  • Integer’s exhibit will spotlight the recent strategic acquisitions of InNeuroCo and Pulse Technologies, each of which have further enhanced Integer’s capability spectrum in the medical device sector.
  • The acquisition of InNeuroCo brings specific expertise in neurovascular solutions and advanced catheter technologies, while the combination with Pulse Technologies enhances capabilities in precision micro machining, backed by proprietary technologies and a focus on high-growth medical markets.
  • Cardio and Vascular Solutions: A full range of electrophysiology, structural heart, and neurovascular product solutions including high-performing guidewires, steerable introducers and sheaths, therapy delivery systems, and implant technologies.
  • In addition to Integer’s exhibit at booth #1439, MD&M West 2024 attendees can also visit Pulse Technologies at booth #2844 to learn more about complex micro machining for critical medical device components.

Cardio Diagnostics Holdings, Inc. Accelerates Cardiac Care Innovation with Appointment of Dr. Vimal Ramjee as Strategic Advisor

Retrieved on: 
Wednesday, January 24, 2024
Cardiology, Biotechnology, Technology, Other Health, Health, General Health, Health Technology, Medical Devices, Software, Artificial Intelligence, Genetics, Nuclear medicine, Entrepreneurship, Artificial intelligence, Patient, Internal medicine, Research, American College of Physicians, MD, Cardio, Emory University, JACC, Innovation, University, Algorithm, Journal of Clinical Investigation, FACC, ACP, ACC, Journal, NIH, Cardiovascular disease, Bachelor of Science, Hospital, Society for Vascular Surgery, Mount Sinai School, American College, Growth, Medical device

Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (Nasdaq: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Dr. Vimal Ramjee, MD FACC CCMS , as a Strategic Advisor.
  • The appointment of Dr. Ramjee as a Strategic Advisor to Cardio Diagnostics is a significant development to the Company’s continued growth and market expansion.
  • “I am excited to join Cardio Diagnostics and contribute to the company’s mission of improving cardiovascular health,” said Dr. Ramjee.
  • Dr. Ramjee will also work to raise awareness of Cardio Diagnostics’ innovative technologies and their potential to improve patient care.

Cardio Diagnostics Holdings, Inc. Announces the Grant of a Patent in India

Retrieved on: 
Monday, January 8, 2024
Science, Cardiology, Biotechnology, Research, General Health, Health, Artificial Intelligence, Technology, Genotype, Integration, MD, CHD, Risk, Patent, University, Cardio, Patient, University of Iowa, Cardiovascular disease, Public health, Distribution, Algorithm, Personalized medicine, Pharmaceutical industry

It was co-invented by Cardio Diagnostics’ founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D., the Chief Executive Officer and Chief Medical Officer of the Company, respectively.

Key Points: 
  • It was co-invented by Cardio Diagnostics’ founders, Meesha Dogan, Ph.D., and Robert Philibert, MD, Ph.D., the Chief Executive Officer and Chief Medical Officer of the Company, respectively.
  • This presents a significant opportunity for Cardio Diagnostics to expand its footprint in the world’s fastest growing nation by population .
  • Cardio Diagnostics recently entered into a Supply and Distribution Agreement with Aimil Ltd. , a company at the forefront of the instrumentation industry in India since 1932 with 14 sales and services offices across India.
  • Cardio Diagnostics exemplifies the transformation of cutting-edge research into Precision Medicine solutions with the potential to impact and save lives worldwide."

Cardio Diagnostics Holdings, Inc. Appoints Biotechnology Investor, Executive & Serial Entrepreneur Paul Burton to its Board of Directors

Retrieved on: 
Thursday, December 21, 2023
Health, Technology, General Health, Artificial Intelligence, Cardiology, Biotechnology, Entrepreneurship, Audit committee, FDA, MBA, Doctor of Philosophy, Health equity, University, Citigroup, Cardio, Therapy

Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director.

Key Points: 
  • Cardio Diagnostics Holdings, Inc. (NASDAQ: CDIO), an AI-driven precision cardiovascular medicine company, today announced the appointment of Paul Burton, J.D., MBA to its Board of Directors as an Independent Director.
  • Mr. Burton is the Managing Partner at 2Flo Ventures, an early-stage healthcare investor and startup studio focused on accelerating health equity.
  • "We are thrilled to welcome Paul to Cardio Diagnostics’ Board of Directors," said CEO and Co-Founder Meesha Dogan, PhD.
  • "I am thrilled to join the Cardio Diagnostics board to help drive the next wave of cardiovascular innovation," said Paul Burton, J.D., MBA, Managing Partner at 2Flo Ventures.

BowFlex Inc. Reports Second Quarter Fiscal 2024 Results

Retrieved on: 
Tuesday, November 14, 2023
Retail, Health, Technology, Fitness & Nutrition, Mobile, Wireless, Specialty, Hardware, Trade, EBITDA, Webcast, Absorption, Feedback, Acquisition, NYSE, Balance sheet, Strength, Motion, Income tax, Advertising, All Access Europe, Investment, Comparison, Cardio, Tax, Public expenditure, PPT, Member, Marketing, Machine learning, Capital, Bowflex, Capital expenditure, Adjustment, Forecasting, Operating cost, BFX, VAY, Growth, Subscription business model, IOS, Lender option borrower option, Environment, Rare-earth element, Music, Aquaculture, Reinsurance, Bookkeeping, Cryptocurrency, Pharmaceutical industry, Mobile phone, Video game, Health care, Android

BowFlex Inc. (NYSE: BFX) today reported its unaudited operating results for the fiscal 2024 second quarter ended September 30, 2023.

Key Points: 
  • BowFlex Inc. (NYSE: BFX) today reported its unaudited operating results for the fiscal 2024 second quarter ended September 30, 2023.
  • Fiscal 2024 Second Quarter Ended September 30, 2023 Compared to September 30, 2022
    Direct segment sales were $20.7 million, compared to $24.5 million, a decline of 15.3% versus the same period in 2022.
  • The increase in inventory in the second quarter of fiscal 2024 versus the fiscal year ended March 31, 2023 was driven by inventory purchases in anticipation of our busy season, which occurs in the third and fourth quarters of our fiscal year.
  • The increase in trade receivables was due to increased Retail sales offset by cash collection efforts in the second quarter of fiscal 2024.

Family Medicine Specialists Selects Cardio Diagnostics’ Epigenetic-Genetic Tests for Assessing Heart Attack Risk for its BlueCross BlueShield Patients

Retrieved on: 
Tuesday, November 7, 2023
Technology, Biotechnology, Health, Biometrics, Other Health, Artificial Intelligence, Practice Management, Software, General Health, Genetics, Health Technology, Health Insurance, Data Management, Cardiology, Cardio, Splenic infarction, HMO, Obesity, Bangladesh Technical Education Board, Conditional sentence, Diabetes, Organization, Entrepreneurship, Milken Institute, Death, CDC, Risk, PPO, Hypertension, Blue Cross Blue Shield Association, Moyamoya disease, Patient, FMS, CHD, Cardiovascular disease, Heart failure, Medical device, Pharmaceutical industry, Medicaid

The "Heart Attack Prevention" initiative will leverage Cardio Diagnostics' advanced and highly sensitive blood-based epigenetic-genetic tests to risk stratify FMS’ patient population.

Key Points: 
  • The "Heart Attack Prevention" initiative will leverage Cardio Diagnostics' advanced and highly sensitive blood-based epigenetic-genetic tests to risk stratify FMS’ patient population.
  • According to the CDC, nearly 50% of Americans have at least one major cardiovascular risk such as diabetes, obesity, or hypertension.
  • FMS is implementing Cardio Diagnostics’ heart attack risk assessment test, Epi+Gen CHD, in at least 1,200 patients with CHD risk factors with BlueCross BlueShield Medicare, Medicaid, HMO and PPO health plans.
  • This initiative will demonstrate the practical and cost-effective benefits of early heart attack risk detection and intervention.

Cardio Diagnostics Holdings, Inc and Aimil Ltd Join Forces to Introduce Cardiovascular Epigenetic Technologies to India

Retrieved on: 
Tuesday, October 17, 2023
Technology, Medical Devices, General Health, Science, Genetics, Medical Supplies, Clinical Trials, Cardiology, Biotechnology, Health, Health Technology, Other Science, Research, Other Technology, Software, Other Health, Artificial Intelligence, Cardiovascular disease, Sumathi Best Television Current Reporting Award, Death, Distribution, Prevalence, Organization, Calibration, CCTA, Radiation, Cardio, R, Laboratory, CVD, Global Burden of Disease Study, Artificial intelligence, Entrepreneurship, CHD, Growth, Supply, Evaluation, NABL, Moyamoya disease, Security (finance), Institute for Health Metrics and Evaluation, Medical device, Pharmaceutical industry

This strategic venture between Cardio Diagnostics and Aimil seeks to address the growing prevalence of heart disease in India through the introduction of Cardio Diagnostics’ clinical test, PrecisionCHD, for the detection and personalized management of coronary heart disease (CHD).

Key Points: 
  • This strategic venture between Cardio Diagnostics and Aimil seeks to address the growing prevalence of heart disease in India through the introduction of Cardio Diagnostics’ clinical test, PrecisionCHD, for the detection and personalized management of coronary heart disease (CHD).
  • With Cardio Diagnostics’ PrecisionCHD test, there is a significant opportunity to reduce the burden of CHD across India.
  • “Heart disease is a global problem and Cardio Diagnostics’ expansion to India underscores our commitment to combat heart disease globally.
  • Cardio Diagnostics is an artificial intelligence-powered precision cardiovascular medicine company that makes cardiovascular disease prevention, detection, and management more accessible, personalized, and precise.